Literature DB >> 9776129

Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist.

C A Heidbreder1, S Schenk, B Partridge, T S Shippenberg.   

Abstract

Previous data have shown that the repeated administration of kappa-opioid receptor agonists attenuates the acute behavioral effects of cocaine. The site and mechanism by which kappa-agonists interact with this psychostimulant, however, are unknown. Accordingly, the present microdialysis study characterized the effects of prior, repeated administration of the selective kappa-opioid receptor agonist U69593 on basal and cocaine-evoked DA levels within the nucleus accumbens (NAC) and caudate putamen (CPU). The influence of U69593 treatment on the locomotor-activating effects of an acute cocaine challenge was also assessed. Rats received once daily injections of U69593 (0.16-0.32 mg/kg/day) or vehicle (1.0 ml/kg/day) for 3 days. The behavioral and neurochemical effects produced by an acute cocaine challenge (20 mg/kg i.p.) were assessed 2 days following treatment cessation. Administration of cocaine to control animals increased locomotor activity. This effect was attenuated in animals which had previously received U69593 (0.32 mg/kg/day x 3 days). Prior administration of U69593 failed to modify basal DA levels in either the NAC or CPU. Thus, 2 days following the cessation of U69593 treatment, dialysate DA levels did not differ from that of controls. Administration of cocaine to vehicle-treated animals increased dialysate levels of DA in both brain regions. However, in animals previously exposed to U69593 (0.32 mg/kg/day x 3 days), a significant enhancement in the response of DA neurons to cocaine was seen. These data demonstrate that prior, repeated administration of a selective kappa-opioid receptor agonist attenuates the locomotor-activating effects of cocaine and increases cocaine-evoked DA overflow in terminal projection areas of mesostriatal and mesolimbic DA neurons. These findings indicate that the behavioral interactions of kappa-agonists with cocaine observed in this and previous studies cannot be attributed to a presynaptic inhibition of DA release. Rather, they suggest that postsynaptic or non-DA mechanisms mediate the interaction of these agents with cocaine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9776129     DOI: 10.1002/(SICI)1098-2396(199811)30:3<255::AID-SYN3>3.0.CO;2-A

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  19 in total

Review 1.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

2.  Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.

Authors:  David N Potter; Diane Damez-Werno; William A Carlezon; Bruce M Cohen; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2011-07-14       Impact factor: 13.382

Review 3.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

Review 4.  The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?

Authors:  Ji Hoon Yoo; Ian Kitchen; Alexis Bailey
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 5.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

6.  The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat.

Authors:  Hugo A Tejeda; Vladimir I Chefer; Agustin Zapata; Toni S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

Review 7.  A Motivational and Neuropeptidergic Hub: Anatomical and Functional Diversity within the Nucleus Accumbens Shell.

Authors:  Daniel C Castro; Michael R Bruchas
Journal:  Neuron       Date:  2019-05-08       Impact factor: 17.173

Review 8.  Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Authors:  Bronwyn M Kivell; Amy W M Ewald; Thomas E Prisinzano
Journal:  Adv Pharmacol       Date:  2014

9.  Differential time course of effects of kappa-opioid agonist treatment on dynorphin A levels and kappa-opioid receptor density.

Authors:  Claudio D'Addario; Manuela Di Benedetto; Sari Izenwasser; Sanzio Candeletti; Patrizia Romualdi
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 10.  Drug withdrawal conceptualized as a stressor.

Authors:  Elena H Chartoff; William A Carlezon
Journal:  Behav Pharmacol       Date:  2014-09       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.